Shares held by institutions ARE included in the float, institutional shares are NOT restricted in any way by the SEC from being openly traded on the market, i.e. there's no lock-up period or company notification filing needed to trade them. The only way the float goes down is if the company buys back shares on the open market.
Yes, in principle, sooner or latter aveo will need to raise cash (finance r&d, but not borrow to do it) over and above revenue, and they'll need mc to do that. Hedge funds can't keep vamping the mc, unfortunately hedge funds don't understand organic growth, they think tomorrow, how can we screw everybody else and get fatter and fatter, this is the post-modern (mostly controlled by hfs) market conundrum.
1) It's been over three years now since the magnitude of the hedge fund phenomena has been publicly documented. In 2012 hedge funds made over 50% of all trades, each and every day, and controlled over $2T in market assets. Hedge funds run the market. No one knows for sure how much worse it's gotten, but you can bet it's gotten worse, it was growing at better that 20% in 2012! So this is NOT your father's stock market, it not even the same market it was five years ago. (I'm confident that all retail longs recognize this.) Short term retail swing trading on technicals, fundamentals, anything but thinking like an unregulated bunch of crooks is a waste of time. Thankfully this stock has just became less vulnerable to an IP attack (a decision the hedgies made, it's obviously in the main cabal's interest) and is now a long term (1-2 yrs?) hold, a good one, and cheap right now, the model here is NBIX imo.
2) Also, surprise, surprise, its opex week (my guess, nobody with calls or puts will make any money this week), indeed, aveo mgmt are earning their money, but they are not in charge.
Feuerstein's opinion is from an April 2013 video, his guess is the FDA committee will vote negative, but says FDA committee could go either way, in any event all of this is well before the low NRP-1 phase 2 study results coming out (about 1/3 of the CRC market), and the 902 third line consideration of the FDA for RCC.
Note that Feuerstein has been particularly identified as a hedge fund shorting tool, search "Expose Adam Feuerstein". Of course the fact that Feuerstein and virtually all majority of ws opinionists make a living helping hedge fund cabals short stocks they control shouldn't shock anyone. Nevertheless, the fact that this deal is as significant as it is, is a really good long term sign for this stock. Denner and his pals are not likely to collapse the company now and steal the IP (a la ENZON), with Novartis dangling on his tzitzit. Will the hedgies run it up and down sawtooth style a dozen times before they cash out, you bet!
AVEO mgmt doing a good job of slowing cash drain but apparently have no skills at moving things forward or making pharma deals. Hedge fund mgmt has left second or third stringers in charge and they're playing for options and short change. Time is a wasting, the half billion dollars of sunk investment here, positive stats are going to go to waste if hedge fund biggies don't take a few minutes to sign in from their yachts and catch up on the poor job their underlings are doing.
Offering, what offering?, the only sec filing related to any offering is the Feb 27, 2015 prospectus supplement, is that what you're talking about?
will be interesting to see if there's a flurry of nonsense post, to bury this thread, typical hedge fund tactics to get the truth off the radar screen
1) Mgmt knew what the data was going to say at least a month if not two or three before they made an announcement. So they should have been aggressively seeking a partner months ago.
2) Cash is getting low, with each month their position to negotiate gets weaker, negotiators will push for more concessions, anything can happen in the market broadly, Spain could be next, who knows when they'll get to sell the shelf, which they should have done back in March when they had a price spike that they created.
3. The data is good, real good, small sample but it would be very very unlikely to change completely, and you don't announce statistics like that and then be caught lying, that kind of #$%$ almost never happens. But the hedge fund crooks that effectively run the show could have mgmt spend all the cash and then, OH NO, we're out of money, FIRE SALE, and some no-name privately held biopharma buys all the goodies for squat! That kind of sheet happens a lot nowadays, and certainly could be in the works, and with each passing day/missed opportunity it looks more and more likely imo.
Denner and his hedge fund buddies must be playing poker with the shares, no other explanation for the churn this stock has.
Ultimate scam artists, spoof it up, short it down, why bother giving their trolls a response fee?
the questions are financial,
1) Why didn't MLV take advantage of the March 21st run-up and reload cash with $16M+ (after fees) of security cash?
(If the pipeline can be partnered (minus cachexia, a wound licking and costly mistake) as it looks like it can (sub population stats are good, very good), the dilution would have been insignificant compared to the leverage gained imo.)
2) What are the performance achievements needed to differ the onset $18M in loan repayment? Is the Q3 2016 cash burn redline contingent on meeting the performance objectives?
As a general observation AVEO has been been less than upfront with their financials. This is a bad practice, the optics are negative, if they are going to instill confidence in the marketplace and be a pharma player. Then again, if they're going to pull a fast one for the hedge fund warlocks, i.e., jump to bankruptcy and have a fire sale of the IP, it looks pretty typical of ws crooks running the show, playing saw-tooth pump and dump till the aw-ow cash run-out, and then IP ripe off.
Mr. Bailey, will you change the mindset, show your hand, and deal an straight game?
Up 10%+ on no news, after a 20% dive due to poor communications, mm engine room trolls trying to make a few bucks, or the 5%ers getting some good news, who cares right, green, euphoria for the huddled masses, manna from the ws crooks running the show
All the hubbub is about the FDA guidance re CRC. It's as clear as day that prospective evidence for NPR-1 biomarker subpopulation re the March 6 CRC PR, i.e., "PFS when treated with tivozanib (17.9 months, n=52), compared to bevacizumab (11.2 months, n=28) (HR=0.380, p=0.0075)" is statistically, very very promising, but!, this was a prospective analysis and result for a subpopulation of the 265 patient BATON intent to treat population. It's obvious that the FDA would make exactly the recommendation they made in the PR released today. Don't stop, make a biomarker specific population assessment before proceeding. This is no news, it's totally expected. Did we expect the FDA to say, don't waste your time, no, did we expect the FDA to say proceed to phase III based on your prospective analysis of the BATON study, NO (clear from reading the March 6th PR). So this is just mgmt reporting out obvious, predictable FDA response, which they could have done a better job of presenting imo.
cpp's right, trolls have been working this board heavily for the past couple of months, whenever that happens it's almost certain something is going on with a stock that will take it up, most likely a buyout. As for the pr, it's clear that it's a none event, but what's interesting is how management has spun it, remember!, they're owned and operated by hedge funds.
I've read this in various other web postings, but never validated it, so I called my broker (TDA) and asked, according to them the only way to prevent borrowing of shares, from a TDA margin account, is to have no margin debit. (Not a solution for the huddled masses obviously!)
Also for what looks to be a fairly credible discourse on the topic suggest googling
'tradeking shorting a stock how to prevent it alphaking'
Note the reference to SEC Rule 15c3-3 (as per usual, long and nearly incomprehensible).
The long and short of it appears to be, retails save brokerage fees at the expense of hedge funds borrowing and shorting their holdings, and driving the value of the holdings down.
Tough to be at the bottom of the food chain!
Suggest setting a $15 sell limit order, put some pressure on the troll meisters to pull back the likely 10-20 mil counterfite shares (FTDs) the dtcc is letting the mms play fast and loose with!